April W. Armstrong, MD, MPH / Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP - Next-Generation Treatments for Moderate-to-Severe Plaque Psoriasis: What's New in TYK2

episode

CME in Minutes: Education in Primary Care not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

The Ezra Klein Show: Jensen Huang Thinks A.I. Alarmism Has Gone Too Far 1h 50m · 25 Sep 2026 · Hard Fork

Pretty Little Episode #110 26 min · 25 Sep 2026 · Handsome

Be Upfront About How You Make Money From Your Podcast 2 min · 25 Sep 2026 · One Minute Podcast Tips - Be a Better Podcaster in Just 60 Seconds

High Stakes US-China Sit Down & Flock Surveillance Under Scrutiny | 9.25.26 19 min · 25 Sep 2026 · Morning Wire

Trump Spooked by Plane at Xi Meeting & Sen. Tuberville Rails Against Flying Furries | Merritt Wever 37 min · 25 Sep 2026 · The Daily Show: Ears Edition

Ireland collapse in Kosovo as Israel game looms 13 min · 25 Sep 2026 · Today with David McCullagh

Report any issue

Source

Recorded04 Aug 2025

Publisherc.answersincme.com ↗

Handlerec:10296226

Show notes

Please visit answersincme.com/JCY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in dermatology discuss the current and potential clinical impact of TYK2 inhibitors. Upon completion of this activity, participants should be better able to: Contrast the clinical implications of selective TYK2 inhibition versus pan-JAK inhibition in the treatment of moderate-to-severe plaque psoriasis; Interpret the clinical evidence for next-generation TYK2 inhibitors in patients with moderate-to-severe plaque psoriasis; and Integrate TYK2 inhibitors into clinical practice as they become available for patients with moderate-to-severe plaque psoriasis.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in